Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem
- 6 March 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 15 (3), 249-259
- https://doi.org/10.1007/s11912-013-0308-6
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working GroupCritical Reviews in Oncology/Hematology, 2012
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupportive Care in Cancer, 2011
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Array of cutaneous adverse effects associated with sorafenibJournal of the American Academy of Dermatology, 2009
- Dermatologic symptoms associated with the multikinase inhibitor sorafenibJournal of the American Academy of Dermatology, 2009
- Nævus éruptifs sous sorafénibAnnales de Dermatologie et de Vénéréologie, 2008
- Sorafenib-Induced Eruptive Melanocytic LesionsArchives of Dermatology, 2008
- Regulation of MAPKs by growth factors and receptor tyrosine kinasesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Mutations of the BRAF gene in human cancerNature, 2002